New pill plus chemo shows promise in early AML trial

NCT ID NCT06497062

Ongoing Disease control Sponsor: Shanghai Jiao Tong University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests a new targeted drug called sonrotoclax (taken as a pill) combined with standard chemotherapy in 47 adults newly diagnosed with acute myeloid leukemia (AML). The treatment plan is adjusted based on each patient's genetic risk and response. The goal is to see if this combination is safe and improves remission and survival rates.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sonrotoclax (a targeted cancer drug taken as a pill)
What this could lead to: If successful, this could offer a more effective treatment option for newly diagnosed acute myeloid leukemia, potentially improving remission rates and survival.
What could go wrong: This is an early-phase (Phase 2) study with only 47 participants, so results may not apply to all patients. The drug may cause side effects or fail to improve outcomes compared to standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

Ruijin Hospital, Shanghai Jiaotong University School of Medicine

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.